Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rengalin for cough in children with acute viral URTI
NCT07171099Phase 3Recruiting
- Sponsor
- Materia Medica Holding
- Start
- Oct 2025
- Primary completion
- Dec 2028
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 3 trial of Rengalin in cough, upper respiratory tract infection (URI), sponsored by Materia Medica Holding. Started Oct 2025; status: recruiting.
02
Drugs
Rengalin
03
Conditions
coughupper respiratory tract infection (URI)
Beyond the preview
Go deeper on NCT07171099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07171099.